701 Gateway Blvd Ste 210
South San Francisco, CA, 94080 United States
OXiGENE is a biopharmaceutical company focused on vascular targeted therapy in oncology, which starves cancer to death. Its vascular targeted therapy include vascular disrupting agents (VDAs) and anti-angiogenic agents (AAs). VDAs selectively obstruct a tumor's blood supply without obstructing the blood supply to normal tissues, and treatment with our VDAs has been shown to lead to significant central tumor necrosis. OXiGENE believes that the treatment of cancer is significantly improved if VDAs and AAs are used together. The company's strategy is to identify and license compounds from academic research centers and then shepherd the compounds through clinical trials.